Synthesis and biological evaluation of 99mTc-DHPM complex: a potential new radiopharmaceutical for lung imaging studies

  • Kakali De
  • Susmita Chandra
  • Bhart Sarkar
  • Santanu Ganguly
  • Mridula Misra
Article
First Online:
Received:

Abstract

In the recent years interests on dihydropyrimidinone and their analogues have increased potentially due to their wide range of pharmacological/biological activities. Synthesis, radiolabeling with technetium-99 m (99mTc) and biological evaluation of 5-etoxycarbonyl-4-phenyl-6-methyl-3,4-dihydro-(1H)-pyrimidine-2-one (DHPM) were studied in this present work. After synthesis complexation of DHPM with 99mTc was carried out using stannous chloride as the reducing agent. The complex (99mTc-DHPM) was characterized by thin layer chromatography, radio-HPLC technique and determination of partition co-efficient. Radiochemical stability and particle size distribution of the complex were also measured. Biodistribution/scintigraphy studies were performed in rats and rabbits to evaluate the pharmacological characteristics of this complex. The radiochemical purity of the complex was over 95% as studied by thin layer chromatography and radio-HPLC. It was stable over 24 h at room temperature. Its partition coefficient indicated that it was a lipophilic complex. According to the European Pharmacopeia, >80% of 99mTc labeled radiopharmaceutical (99mTc-MAA) in the size range 10–50 μm, must be accumulated in the lungs 15 min after intravenous administration. In this study >85% of the 99mTc-DHPM complex in the average size of 40 μm. Biodistribution studies of 99mTc-DHPM in rat revealed that the complex accumulated in the lung with high uptake and good retention after intravenous administration. Scintigraphic studies in rabbit also revealed that most of the administered radiolabeled complex was accumulated in the lungs and after 1 h slowly excreted through the renal system. The lung uptake (ID%/g) was 10.12, 9.67, 8.60 and 5.01 and the lung/liver ratio was 7.49, 2.88, 2.62 and 1.87 at 2, 15, 30 and 60 min post-injection, respectively. These results suggested that 99mTc-DHPM could be suitable as a potential lung perfusion imaging agent. Further studies with 99mTc-DHPM and its derivatives are warranted to develop new 99mTc-labeled imaging agents for clinical applications.

Keywords

Technetium-99m Biodistribution Scintigraphic Lipophilic Lung uptake 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgments

We are thankful to Indian Council of Medical Research (ICMR), New Delhi, India for providing financial support.

References

  1. 1.
    Maiti G, Kundu P, Guin C (2003) Tetrahedron Lett 44:2757–2758CrossRefGoogle Scholar
  2. 2.
    Kalita HR, Phukan P (2007) Catalysis Commun 8:179–182CrossRefGoogle Scholar
  3. 3.
    Bryzgalov OA, Dolgikh MP, Sorokina IV, Tolstikova TG, Sedova VF, Shkurko OP (2006) Bioorg Med Chem Lett 16:1418–1420CrossRefGoogle Scholar
  4. 4.
    Sharma SD, Gogoi P, Konwar D (2007) Green Chem 9:153–157CrossRefGoogle Scholar
  5. 5.
    Patil AD, Kumar NV, Kokke WC, Bean MF, Freyer AJ (1995) J Org Chem 60:1182–1188CrossRefGoogle Scholar
  6. 6.
    Biginelli P (1893) Gazz Chim Ital 23:360–416Google Scholar
  7. 7.
    Kappe CO (1993) Tetrahedron 49:6937–6963CrossRefGoogle Scholar
  8. 8.
    Atwal KS, Swanson BN, Unger SE, Floyd SM, Hedberg A, Oreilly BC (1991) J Med Chem 34:806CrossRefGoogle Scholar
  9. 9.
    Zhang J, Wang X, Liu J (2005) J Appl Radiat Isot 62:33–37CrossRefGoogle Scholar
  10. 10.
    Liu S, He Z, Hsieh WY, Kim YS (2006) Nucl Med Biol 33:419–432CrossRefGoogle Scholar
  11. 11.
    Ilyas M, Haider HKH, saeeda A, Javed M, Shams Z, Sameera C (1998) Med J Islamic Acad Sci 11:131–138Google Scholar
  12. 12.
    Pistolesi M, Miniati M (2002) Eur Respir J Suppl 35:28s–39sCrossRefGoogle Scholar
  13. 13.
    Worsley DF, Alavi A (2003) Semin Nucl Med 33:259–278CrossRefGoogle Scholar
  14. 14.
    Hunt AP, Frier M, Johnson RA, Berezenko S, Perkins AC (2006) Eur J Pharm Biopharm 62:26–31CrossRefGoogle Scholar
  15. 15.
    Delgado A, Soriano I, Sanchez E, Oliva M, Evora C (2000) Eur J Pharm Biopharm 50:227–236CrossRefGoogle Scholar
  16. 16.
    Farmacopea Europea (1991) Publicaciones, Documentacion y Biblioteca del Ministerio de Sanidad y Consumo, 2nd ed, vol 7, MadridGoogle Scholar
  17. 17.
    Zophel K, Bacher-Stier C, Pinkert J (2009) Ann Nucl Med 23:1–16CrossRefGoogle Scholar
  18. 18.
    Chia HL (1987) Particulate radiopharmaceuticals in nuclear medicine. In: Cox PH (ed) Radiopharmacy and radiopharmacology yearbook 2. Gordon and Breach science, New YorkGoogle Scholar
  19. 19.
    Hisose Y, Imaeda T, Doi H, Mitsubhara K, Satoshi S, Hirose H (1993) Ann Nucl Med 7:123–126CrossRefGoogle Scholar
  20. 20.
    Van-Nerom C, Deltrue M, Mormans G, De-Roo M, Verbruggen A (1988) Nuclearir-Geneeskundig-Bulletin 10:69–75Google Scholar
  21. 21.
    Macrotec package insert (Squibb-US), Rev 3/87; Technetium Tc 99 m MAA (Medi-Physics–US), Rev 7/87Google Scholar
  22. 22.
    Misra M, Sarkar HS, Chakravarty M, Sanyal S, Ganguly S (1994) Nucl Med Comm 15:878–885CrossRefGoogle Scholar
  23. 23.
    Bolzati C, Uccelli LRF, Tisato F, duatti A, Giganti M, Piffanelli A (1998) Nucl Med Biol 25:71–76CrossRefGoogle Scholar
  24. 24.
    Johansen B, Syhre R, Spies H, Munze R (1978) J Nucl Med 19:816–824Google Scholar
  25. 25.
    Kung HF, Molnar M, Billings J, Wicks R, Blau M (1984) J Nucl Med 25:326–332Google Scholar
  26. 26.
    Luo TY, Hsieh BT, Wang SJ, Lin WY, Lee TW (2004) Nucl Med Biol 31:671–677CrossRefGoogle Scholar
  27. 27.
    Mukherjee S, Chatterjee J, Punyabrata D, Sengupta C, Banerjee S (1993) J Nucl Med 20:413–426CrossRefGoogle Scholar
  28. 28.
    Koslowsky IL, Brake SE, Bitner SJ (2001) J Nucl Med Tech 29:197–200Google Scholar
  29. 29.
    Kothari K, Banerjee S, Sarma HD, Pillai MRA (2000) App Radiat Isot 52:69–76CrossRefGoogle Scholar
  30. 30.
    Liu X, Tanaka H, Yamauchi A, Testa B, Chuman HJ (2005) Chromatogr A 1091:51–59CrossRefGoogle Scholar
  31. 31.
    Teran M, Savio E, Paolino A, Frier M (2004) Eur J Pharm Biopharm 57:347–352CrossRefGoogle Scholar
  32. 32.
    Misra M, Das BK, Gambhir S, Mittal BR, Sewatkar AB, Ghosh S, Banerjee SN (1994) Clin Nucl Med 19:314–320CrossRefGoogle Scholar
  33. 33.
    Ertay T, Unak P, Tasci C, Zihnioglu F, Durak H (2005) App Radiat Isot 62:883–888CrossRefGoogle Scholar
  34. 34.
    Vanbilloen HP, Cleynhens BJ, Verbruggen AM (2000) Nucl Med Biol 27:207–214CrossRefGoogle Scholar
  35. 35.
    Narra RK, Nunn AD, Kuczynski BL, Dirocco RJ, Feld T, Silva DA, Eckelman WC (1990) J Nucl Med 31:1370–1377Google Scholar
  36. 36.
    Walovitch RC, Hill TC, Garrity ST, Cheesman EH (1989) J Nucl Med 30:1892–1901Google Scholar
  37. 37.
    Hong YD, Jang BS, Choi SM (2004) Appl Radiat Isot 61:1273–1278CrossRefGoogle Scholar
  38. 38.
    Bhatnagar A, Sawroop K, Chopra MK, Kumar N, Jaimini A (2008) Nucl Med Commun 29:987–993CrossRefGoogle Scholar
  39. 39.
    Vanlic-Razumenic N (1999) J Radioanal Nucl Chem 242:235–240CrossRefGoogle Scholar
  40. 40.
    Fennerty T (1997) Br Med J 314:425–429Google Scholar
  41. 41.
    Kruip MJ, Leclercq MG, Van Der Heul C, Prins MH, Buller HR (2003) Ann Intern Med 138:941–951Google Scholar
  42. 42.
    Ibrahim IT, Wally MA (2009) J Radioanal Nucl Chem. doi: 10.1007/s10967-009-0039-1
  43. 43.
    Amir N, Roohi S, Pervez S, Mushtaq A, Jehangir M, Miyashita Y, Okamoto K (2009) J Radioanal Nucl Chem 279:25–30CrossRefGoogle Scholar

Copyright information

© Akadémiai Kiadó, Budapest, Hungary 2009

Authors and Affiliations

  • Kakali De
    • 1
  • Susmita Chandra
    • 1
  • Bhart Sarkar
    • 2
  • Santanu Ganguly
    • 2
  • Mridula Misra
    • 1
  1. 1.Department of Nuclear MedicineIndian Institute of Chemical BiologyKolkataIndia
  2. 2.Regional Radiation Medicine Centre, Thakurpukur Cancer Research CentreKolkataIndia

Personalised recommendations